BostonGene and Collaborators Honored with GRASP Advocate Choice Award at the 2024 ASCO Annual Meeting
BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced the presentation of its poster at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting has received the GRASP Advocate Choice Award. The poster details the results of a study that uncovered the intricate heterogeneity of the tumor microenvironment (TME) in invasive lobular carcinoma (ILC) of the breast, through bulk RNA-seq and spatial biology analyses, highlighting the importance of TME profiling in developing personalized treatments for ILC patients.
GRASP (Guiding Researchers and Advocates to Scientific Partnerships) is a nonprofit, patient-led organization that connects patients, clinicians and researchers to exchange ideas and make faster progress in improving treatments and ending cancer. Founded in 2019 by two breast cancer survivors and advocates, GRASP aims to break down silos and foster connections within the cancer community. The 2024 GRASP event will be held in conjunction with the ASCO Annual Meeting on June 12-13, 2024.
The study, "The Multiomic Tumor Microenvironment Landscape of Invasive Lobular Carcinoma of the Breast," was presented by Jason Mouabbi, MD, assistant professor of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center. This research is a collaborative effort between BostonGene and MD Anderson.
The findings revealed 13 primary cell populations and 25 distinct immune and stromal cell subtypes within the TME of ILC. It demonstrated concordance between RNA-seq profiles and spatial biology characteristics, revealing notable differences among various subtypes in RNA and multiplex immunofluorescence (MxIF) data. This multiomic approach provides a baseline for understanding the nuances of the TME in ILC, highlighting unique opportunities for developing novel therapies and combinations.
"Receiving this award is a testament to our dedication to cancer research and advancing patient care through innovative solutions," said Krystle Nomie, PhD, VP of Research Partnerships at BostonGene. "Our collaborative efforts in TME profiling are vital in unraveling the complexities of ILC and tailoring personalized treatments for patients."
About BostonGene Corporation
BostonGene powers an AI model of tumor and immune biology to deliver disease-level insights and enable precision decision-making across oncology and immune-mediated diseases, spanning drug development and clinical care. By integrating multimodal data, including genomic, transcriptomic, immune, and clinical signals, BostonGene generates biologically grounded intelligence to optimize patient selection, trial design, and therapeutic strategy. This creates a scalable AI decision layer that improves development outcomes and clinical management. BostonGene partners with leading biopharmaceutical organizations and academic institutions to accelerate the delivery of precision therapies while continuously expanding its capabilities across new diseases and complex biological systems. For more information, visit www.BostonGene.com.
Latest news
